×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
VRNA – verona pharma plc - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
VRNA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/20
05:31 pm
vrna
Chronic Refractory Cough Market Still Unexplored, with Pharma Companies Eyeing First-Mover Advantage in the US | DelveInsight
Low
Report
Chronic Refractory Cough Market Still Unexplored, with Pharma Companies Eyeing First-Mover Advantage in the US | DelveInsight
11/20
05:31 pm
vrna
Chronic Refractory Cough Market Still Unexplored, with Pharma Companies Eyeing First-Mover Advantage in the US | DelveInsight
Low
Report
Chronic Refractory Cough Market Still Unexplored, with Pharma Companies Eyeing First-Mover Advantage in the US | DelveInsight
11/19
02:08 am
vrna
Verona Pharma Announces December 2024 Investor Conference Participation [Yahoo! Finance]
Medium
Report
Verona Pharma Announces December 2024 Investor Conference Participation [Yahoo! Finance]
11/19
02:00 am
vrna
Verona Pharma Announces December 2024 Investor Conference Participation
Medium
Report
Verona Pharma Announces December 2024 Investor Conference Participation
11/14
03:12 am
vrna
Actimed Therapeutics Announces Professor David Ebsworth to Become Executive Chairman [Yahoo! Finance]
Medium
Report
Actimed Therapeutics Announces Professor David Ebsworth to Become Executive Chairman [Yahoo! Finance]
11/14
03:00 am
vrna
Actimed Therapeutics Announces Professor David Ebsworth to Become Executive Chairman
Medium
Report
Actimed Therapeutics Announces Professor David Ebsworth to Become Executive Chairman
11/12
05:31 pm
vrna
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight
Medium
Report
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight
11/12
05:31 pm
vrna
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight
Medium
Report
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/6
05:52 pm
vrna
Form 4 Verona Pharma plc For: Dec 04 Filed by: ZACCARDELLI DAVID
Low
Report
Form 4 Verona Pharma plc For: Dec 04 Filed by: ZACCARDELLI DAVID
12/6
05:50 pm
vrna
Form 4 Verona Pharma plc For: Dec 04 Filed by: Hahn Mark W
Low
Report
Form 4 Verona Pharma plc For: Dec 04 Filed by: Hahn Mark W
12/2
07:20 pm
vrna
Form 4 Verona Pharma plc For: Nov 27 Filed by: Hahn Mark W
Low
Report
Form 4 Verona Pharma plc For: Nov 27 Filed by: Hahn Mark W
12/2
07:19 pm
vrna
Form 4 Verona Pharma plc For: Nov 27 Filed by: ZACCARDELLI DAVID
Low
Report
Form 4 Verona Pharma plc For: Nov 27 Filed by: ZACCARDELLI DAVID
11/26
06:37 pm
vrna
Form 4 Verona Pharma plc For: Nov 25 Filed by: Hahn Mark W
Low
Report
Form 4 Verona Pharma plc For: Nov 25 Filed by: Hahn Mark W
11/26
06:36 pm
vrna
Form 4 Verona Pharma plc For: Nov 25 Filed by: ZACCARDELLI DAVID
Low
Report
Form 4 Verona Pharma plc For: Nov 25 Filed by: ZACCARDELLI DAVID
11/26
06:34 pm
vrna
Form 4 Verona Pharma plc For: Nov 25 Filed by: Rickard Kathleen A.
Low
Report
Form 4 Verona Pharma plc For: Nov 25 Filed by: Rickard Kathleen A.
11/25
04:42 pm
vrna
Form 144 Verona Pharma plc Filed by: Rickard Kathleen A.
Low
Report
Form 144 Verona Pharma plc Filed by: Rickard Kathleen A.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/10
Verona Pharma to Report 4 Week Phase 2b COPD Dose-ranging Study Results with Nebulized Ensifentrine on Top of Tiotropium Therapy
26.2%
1/18 VERONA PHARMA P/S (NASDAQ: VRNA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 12.6%
3/31 Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD 12.6%
4/21 VERONA PHARMA P/S (NASDAQ: VRNA) had its price target lowered by analysts at Wedbush from $60.00 to $50.00. They now have an "outperform" rating on the stock. 12.0%
9/3 Verona Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference 8.7%
10/17 Verona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPD 7.6%
11/16 VERONA PHARMA P/S (NASDAQ: VRNA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.9%
5/7 Verona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019 5.2%
4/16 Verona Pharma plc: Results of AGM 4.8%
2/14 Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research 4.2%
1/18 VERONA PHARMA P/S (NASDAQ: VRNA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 12.6%
3/31 Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD 12.6%
4/21 VERONA PHARMA P/S (NASDAQ: VRNA) had its price target lowered by analysts at Wedbush from $60.00 to $50.00. They now have an "outperform" rating on the stock. 12.0%
9/3 Verona Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference 8.7%
10/17 Verona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPD 7.6%
11/16 VERONA PHARMA P/S (NASDAQ: VRNA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.9%
5/7 Verona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019 5.2%
4/16 Verona Pharma plc: Results of AGM 4.8%
2/14 Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research 4.2%
TOP News Decliners
1/13
Verona Pharma shares shoot higher on Phase 2 trial of respiratory drug [MarketWatch]
-28.8%
4/30 Verona Pharma plc: Operational Update and Financial Results for the Three Months Ended March 31, 2020 -28.3%
3/16 2019 Annual Report and Accounts and Notice of AGM -17.8%
3/7 VERONA PHARMA P/S (NASDAQ: VRNA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -12.7%
1/13 VERONA PHARMA P/S (NASDAQ: VRNA) had its price target raised by analysts at Wedbush from $58.00 to $60.00. They now have an "outperform" rating on the stock. -10.9%
4/30 Verona Pharma down 30% on uncertainty with Phase 3 ensifentrine study [Seeking Alpha] -9.2%
2/27 Verona Pharma Reports Financial Results for the Full Year Ended December 31, 2019 and Provides Corporate Update -7.7%
7/29 VERONA PHARMA P/S (NASDAQ: VRNA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $58.00 price target on the stock. -6.8%
8/5 Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD -6.6%
4/1 VERONA PHARMA P/S (NASDAQ: VRNA) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $60.00 price target on the stock. -6.1%
4/30 Verona Pharma plc: Operational Update and Financial Results for the Three Months Ended March 31, 2020 -28.3%
3/16 2019 Annual Report and Accounts and Notice of AGM -17.8%
3/7 VERONA PHARMA P/S (NASDAQ: VRNA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -12.7%
1/13 VERONA PHARMA P/S (NASDAQ: VRNA) had its price target raised by analysts at Wedbush from $58.00 to $60.00. They now have an "outperform" rating on the stock. -10.9%
4/30 Verona Pharma down 30% on uncertainty with Phase 3 ensifentrine study [Seeking Alpha] -9.2%
2/27 Verona Pharma Reports Financial Results for the Full Year Ended December 31, 2019 and Provides Corporate Update -7.7%
7/29 VERONA PHARMA P/S (NASDAQ: VRNA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $58.00 price target on the stock. -6.8%
8/5 Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD -6.6%
4/1 VERONA PHARMA P/S (NASDAQ: VRNA) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $60.00 price target on the stock. -6.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: